KYAN Therapeutics bags US$5M to bridge the cancer care gap using tech

Singapore-based KYAN Therapeutics, a biotech company with novel personalised medicine and drug-dose combination optimisation technology, has closed a US$5 million oversubscribed pre-Series A funding round. Altara Ventures led the round and has been joined by Enterprise Singapore (SEEDS Capital), K3 Ventures, and prominent angel investors. KYAN will use the funds to advance clinical development, expand […] The post KYAN Therapeutics bags US$5M to bridge the cancer care gap using tech appeared first on e27.